JP7123802B2 - ヒト多能性幹細胞由来内分泌前駆細胞からの機能的ベータ細胞の産生 - Google Patents

ヒト多能性幹細胞由来内分泌前駆細胞からの機能的ベータ細胞の産生 Download PDF

Info

Publication number
JP7123802B2
JP7123802B2 JP2018544785A JP2018544785A JP7123802B2 JP 7123802 B2 JP7123802 B2 JP 7123802B2 JP 2018544785 A JP2018544785 A JP 2018544785A JP 2018544785 A JP2018544785 A JP 2018544785A JP 7123802 B2 JP7123802 B2 JP 7123802B2
Authority
JP
Japan
Prior art keywords
cells
stem cell
pluripotent stem
endocrine progenitor
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018544785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510482A5 (enExample
JP2019510482A (ja
Inventor
ニコライ・ストレイアー・クリストファーセン
ウルリク・ドゥーン
マティアス・ハンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2019510482A publication Critical patent/JP2019510482A/ja
Publication of JP2019510482A5 publication Critical patent/JP2019510482A5/ja
Application granted granted Critical
Publication of JP7123802B2 publication Critical patent/JP7123802B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/845—Gamma amino butyric acid [GABA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018544785A 2016-02-24 2017-02-24 ヒト多能性幹細胞由来内分泌前駆細胞からの機能的ベータ細胞の産生 Active JP7123802B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16157181 2016-02-24
EP16157181.5 2016-02-24
PCT/EP2017/054390 WO2017144695A1 (en) 2016-02-24 2017-02-24 Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors

Publications (3)

Publication Number Publication Date
JP2019510482A JP2019510482A (ja) 2019-04-18
JP2019510482A5 JP2019510482A5 (enExample) 2020-04-02
JP7123802B2 true JP7123802B2 (ja) 2022-08-23

Family

ID=55588039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018544785A Active JP7123802B2 (ja) 2016-02-24 2017-02-24 ヒト多能性幹細胞由来内分泌前駆細胞からの機能的ベータ細胞の産生

Country Status (7)

Country Link
US (1) US11274280B2 (enExample)
EP (1) EP3420073B1 (enExample)
JP (1) JP7123802B2 (enExample)
CN (1) CN108699515A (enExample)
ES (1) ES2967942T3 (enExample)
MA (1) MA45747A (enExample)
WO (1) WO2017144695A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014007744A (es) 2011-12-22 2015-01-12 Janssen Biotech Inc Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal.
DE112014002780B4 (de) 2013-06-11 2025-05-22 President And Fellows Of Harvard College SC-ß-Zellen und Zusammensetzungen und Verfahren zur Erzeugung der Zellen
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
MA45747A (fr) 2016-02-24 2019-01-02 Novo Nordisk As Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
MA45502A (fr) * 2016-06-21 2019-04-24 Janssen Biotech Inc Génération de cellules bêta fonctionnelles dérivées de cellules souches pluripotentes humaines ayant une respiration mitochondriale glucose-dépendante et une réponse en sécrétion d'insuline en deux phases
AU2018330499B2 (en) 2017-09-11 2025-01-30 Novo Nordisk A/S Enrichment of NKX6.1 and C-peptide co-expressing cells derived in vitro from stem cells
AU2018370029B2 (en) 2017-11-15 2024-11-07 Vertex Pharmaceuticals Incorporated Islet cell manufacturing compositions and methods of use
IL277025B2 (en) * 2018-03-02 2024-04-01 Vertex Pharma Methods of enhancing stem cell differentiation into beta cells
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
AU2018439389A1 (en) * 2018-08-30 2021-02-18 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
EP3953451A1 (en) 2019-04-08 2022-02-16 Novo Nordisk A/S Generation of pancreatic endoderm from stem cell derived definitive endoderm
TW202115245A (zh) 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
JP2023503302A (ja) 2019-11-22 2023-01-27 ノヴォ ノルディスク アー／エス スピン凝集した神経系マイクロスフェアおよびその応用
US20240226179A1 (en) * 2020-02-28 2024-07-11 The Trustees Of The University Of Pennsylvania Tissue culture media for survival and engraftment of human pancreatic islets
EP4114927A1 (en) 2020-03-02 2023-01-11 Novo Nordisk A/S Use of pluripotent markers to detect contaminating residual undifferentiated pluripotent stem cells
CN116018150A (zh) 2020-08-28 2023-04-25 诺和诺德股份有限公司 用于筛选干细胞衍生的β样细胞的体外群体的方法及其新型标志物
AR124419A1 (es) 2020-12-18 2023-03-29 Novo Nordisk As Células seguras invisibles para el sistema inmunitario
WO2022136215A1 (en) 2020-12-21 2022-06-30 Novo Nordisk A/S Safe immuno-stealth cells
CN113069440A (zh) * 2021-04-08 2021-07-06 澳门大学 甲状腺素的新的应用、培养多能干细胞的方法和培养基
WO2023076554A1 (en) * 2021-10-28 2023-05-04 Memorial Sloan-Kettering Cancer Center Compositions and methods for promoting in vitro maturation of cells
WO2023118050A1 (en) 2021-12-21 2023-06-29 Novo Nordisk A/S Use of novel markers to detect pluripotent stem cells
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025093467A1 (en) 2023-10-31 2025-05-08 Novo Nordisk A/S Methods for preventing unwanted cells arising during differentiation of human pluripotent stem cells

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201167A1 (en) 2013-06-11 2014-12-18 President And Fellows Of Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
JP2015519048A (ja) 2012-04-30 2015-07-09 ユニバーシティー、ヘルス、ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ 膵臓前駆細胞及び機能的β細胞をｈＰＳＣから生成するための方法及び組成物
US20150240235A1 (en) 2012-09-27 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for producing a population of pancreatic beta-cells
US20150250824A1 (en) 2014-03-07 2015-09-10 The Research Foundation For The State University Of New York Methods and compositions for expansion of stem cells and other cells
US20150368616A1 (en) 2013-02-14 2015-12-24 The Cleveland Clinic Foundation Methods for induction of cell fates from pluripotent cells
JP2016503654A (ja) 2012-12-31 2016-02-08 ヤンセン バイオテツク，インコーポレーテツド Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343786B (es) 2009-12-23 2016-11-22 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas.
EP3498825A1 (en) 2010-05-12 2019-06-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US20140234963A1 (en) 2011-06-21 2014-08-21 Novo Nordisk A/S Efficient induction of definitive endoderm from pluripotent stem cells
WO2014033322A1 (en) * 2012-09-03 2014-03-06 Novo Nordisk A/S Generation of pancreatic endoderm from pluripotent stem cells using small molecules
JP2016521971A (ja) 2013-04-23 2016-07-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法１１９条第（ｅ）項に基づき、２０１４年１月２９日出願の米国特許仮出願第６１／９３２，９３５号、２０１３年９月１７日出願の米国特許仮出願第６１／８７８，７６９号、および２０１３年４月２３日出願の米国特許仮出願第６１／８１４，９２０号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、ＹａｑｕｂＨＡＮＮＡ、ＮｏａＮＯＶＥＲＳＨＴＥＲＮ、およびＹｏａｃｈＲＡＩＳによる米国特許出願（発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法（ＩＳＯＬＡＴＥＤＮＡＩＶＥＰＬＵＲＩＰＯＴＥＮＴＳＴＥＭＣＥＬＬＳＡＮＤＭＥＴＨＯＤＳＯＦＧＥＮＥＲＡＴＩＮＧＳＡＭＥ）」）（代理人事件記録簿第５８８７０号）にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。
WO2014179198A1 (en) 2013-04-29 2014-11-06 Wisconsin Alumni Research Foundation Methods for producing insulin-secreting beta cells from human pluripotent stem cells
US20160208215A1 (en) * 2013-08-30 2016-07-21 Novo Nordisk A/S Generation of Endocrine Progenitor Cells from Human Pluripotent Stem Cells Using Small Molecules
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
MA45747A (fr) 2016-02-24 2019-01-02 Novo Nordisk As Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
AU2018439389A1 (en) 2018-08-30 2021-02-18 Novo Nordisk A/S Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519048A (ja) 2012-04-30 2015-07-09 ユニバーシティー、ヘルス、ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ 膵臓前駆細胞及び機能的β細胞をｈＰＳＣから生成するための方法及び組成物
US20150240235A1 (en) 2012-09-27 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for producing a population of pancreatic beta-cells
JP2016503654A (ja) 2012-12-31 2016-02-08 ヤンセン バイオテツク，インコーポレーテツド Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化
US20150368616A1 (en) 2013-02-14 2015-12-24 The Cleveland Clinic Foundation Methods for induction of cell fates from pluripotent cells
WO2014201167A1 (en) 2013-06-11 2014-12-18 President And Fellows Of Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
US20150250824A1 (en) 2014-03-07 2015-09-10 The Research Foundation For The State University Of New York Methods and compositions for expansion of stem cells and other cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Diabetes，2014年，vol.63，p.4197-4205
The EMBO Journal，2014年，Vol.33,No.19，p.2157-2170

Also Published As

Publication number Publication date
EP3420073A1 (en) 2019-01-02
US11274280B2 (en) 2022-03-15
EP3420073C0 (en) 2023-11-08
EP3420073B1 (en) 2023-11-08
WO2017144695A1 (en) 2017-08-31
MA45747A (fr) 2019-01-02
ES2967942T3 (es) 2024-05-06
WO2017144695A9 (en) 2017-10-19
JP2019510482A (ja) 2019-04-18
CN108699515A (zh) 2018-10-23
US20190085295A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
JP7123802B2 (ja) ヒト多能性幹細胞由来内分泌前駆細胞からの機能的ベータ細胞の産生
US20250043247A1 (en) Sc-beta cells and compositions and methods for generating the same
CN102159703B (zh) 多能干细胞的分化
JP6636427B2 (ja) 小分子を用いるヒト多能性幹細胞からの内分泌始原細胞の作製
JP2017012178A (ja) ヒト胚性幹細胞の分化
WO2010091241A2 (en) Compositions and methods for promoting the generation of definitive endoderm
WO2014033322A1 (en) Generation of pancreatic endoderm from pluripotent stem cells using small molecules
US20210230554A1 (en) Generation of functional beta cells from human pluripotent stem cell-derived endocrine progenitors
Sambathkumar et al. Pluripotent stem cell-derived pancreatic progenitors and β-like cells for type 1 diabetes treatment
CN111108190A (zh) 在体外从干细胞衍生的nkx6.1和c-肽共表达细胞的富集
CN113728090B (zh) 从干细胞衍生的定形内胚层生成胰腺内胚层
McGaugh Elucidating the Role of FGF and RA Signaling during Pancreatic Differentiation using hPSC
Cao et al. Alleviation of streptozotocin-induced diabetes in nude mice by stem cells derived from human first trimester umbilical cord
CN120202293A (zh) 遗传工程化细胞
Bonner-Weir et al. Insulin-producing cells derived from stem cells: a potential treatment for diabetes
Arntfield The Implications of Developmental and Evolutionary Relationships between Pancreatic Beta-cells and Neurons

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220810

R150 Certificate of patent or registration of utility model

Ref document number: 7123802

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250